Lisa is based in Tokyo as a managing editor and will be providing editorial coverage of all aspects of Japan’s prescription drug market for Scrip and the Pink Sheet, including company, market, pricing and regulatory developments, as well as helping to further expand our original content in the region through interviews and unique stories. In the longer term, the intention is for Lisa to support, along with the rest of the content team, our broader regional push towards more local-language content, use of multimedia, and thought leadership initiatives.
Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she was covering another fast-moving, high-tech sector, IT, for ITmedia Enterprise in Japan, where several of her stories won quarterly “Best Content” awards and helped significantly expand readership.
Lisa holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada. She is native level bilingual in Japanese and English and also has conversational ability in Mandarin and French. Her interests and hobbies outside work include taking monochrome photos with digital/film cameras and visiting museums.
Latest From Lisa Takagi
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.
Japanese bioventure Stella Pharma is re-designing a Phase II trial for its glioma candidate Steboronine after it was determined the original primary endpoint was not robust enough to prove efficacy, a challenge faced by some others working in the difficult indication. The drug was approved for head and neck cancer in Japan in 2020 and Stella has already announced a new collaboration which may be key to moving forward.